Advertisement

Topics

Biogen Spin-Off Bioverativ To Be Acquired

07:53 EST 31 Jan 2018 | Forbes

Sanofi will acquire Bioverativ (BIVV) for $105 per share. Bioverativ spun from Biogen (BIIB) on Feb. 1, 2017. BIVV has returned 129%. Spin-Offs are 5x more likely to be acquired. Spin-Offs outperform the general market. Both this spin BIVV and BIIB are great examples of this over performance.

Original Article: Biogen Spin-Off Bioverativ To Be Acquired

NEXT ARTICLE

More From BioPortfolio on "Biogen Spin-Off Bioverativ To Be Acquired"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...